Tulbah, A.S. 2025. Formulation and in vitro characterization of inhalable dasatinib-nanoemulsion as a treatment potential against A549 and Calu-3 lung cancer cells. International Journal of Health Sciences. 19, 1 (Jan. 2025), 4–14.